Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and
InventorsZhiya Yu, Catherine M. Ade, Matthew J. Sporn, James C. Yang, Ken-ichi Hanada
Estimating the term…
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by HLA-A3. Related poly peptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
An isolated or purified T-cell receptor (TCR) comprising the amino acid sequences of:
2-4. (canceled).
(canceled).
10-11. (canceled).
15-16. (canceled).
An isolated or purified nucleic acid comprising, from 5′ to 3′, a first nucleic acid sequence and a second nucleotide sequence, wherein the first and second nucleotide sequence, respectively, encode the amino sequences of SEQ ID NOs:
20-21. (canceled).
23-25. (canceled).
28-29. (canceled).
34-40. (canceled).
Dependencies are inferred from the claim text.